RESUMO
PURPOSE/BACKGROUND: Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) commonly co-occur among US military veterans. Oxytocin may have therapeutic value in treating both conditions. The potential for oxytocin to augment affective features common to PTSD and AUD, such as anger, is relevant to inform emerging treatments. METHODS/PROCEDURES: We examined the influence of intranasally administered oxytocin on connections between alcohol craving and stress-induced anger in a sample of 73 veterans (91.3% men) with co-occurring PTSD and AUD. Participants self-administered oxytocin (40 IU) or placebo (saline) 45 minutes before completing the Trier Social Stress Task (TSST). Self-reports of alcohol craving and anger were assessed pre- and post-TSST using a modified visual analog scale. Multiple regression analysis, including main effects for group, baseline craving, and their interaction, was used to predict post-TSST anger. FINDINGS/RESULTS: A marginally significant interaction was observed, suggesting a positive association between baseline craving and anger for those in the oxytocin group (B = 0.65, P = 0.01). Among those reporting low craving, participants in the oxytocin group reported significantly lower post-TSST anger than those in the placebo group. IMPLICATIONS/CONCLUSIONS: The current study is among the first to examine relevant psychosocial moderators that may influence the effects of oxytocin among veterans with comorbid PTSD and AUD. Although oxytocin attenuated ratings of anger after a stress task among those with low baseline craving, findings suggest that oxytocin may not be as effective at reducing anger, a highly salient factor in PTSD, for individuals experiencing high levels of craving. Findings are consistent with the social salience hypothesis and suggest that individual differences in alcohol craving should be considered when evaluating oxytocin as a potential treatment for individuals with comorbid PTSD and AUD.
Assuntos
Sintomas Afetivos , Alcoolismo , Ira/efeitos dos fármacos , Fissura , Ocitocina/administração & dosagem , Transtornos de Estresse Pós-Traumáticos , Veteranos/psicologia , Administração Intranasal , Sintomas Afetivos/tratamento farmacológico , Sintomas Afetivos/etiologia , Alcoolismo/complicações , Alcoolismo/diagnóstico , Alcoolismo/tratamento farmacológico , Alcoolismo/psicologia , Manual Diagnóstico e Estatístico de Transtornos Mentais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Saúde Militar/estatística & dados numéricos , Técnicas Psicológicas , Transtornos de Estresse Pós-Traumáticos/complicações , Transtornos de Estresse Pós-Traumáticos/diagnóstico , Transtornos de Estresse Pós-Traumáticos/tratamento farmacológico , Transtornos de Estresse Pós-Traumáticos/psicologia , Tranquilizantes/administração & dosagem , Resultado do TratamentoRESUMO
Background and Objectives: Prior research has identified that sources of prescription drugs for misuse vary based on educational attainment, which is important as certain sources are associated with adverse outcomes. The current research addressed limitations of the extant literature by creating distinct categories of push factors for high school dropout (e.g., negative school performance/experiences), pull factors for high school dropout (e.g., starting a family or getting a job), and high school graduates who did not attend college.Methods: Using data from the 2009-2014 National Survey on Drug Use and Health, prevalence of sources were estimated and design-based multivariable logistic regression investigated the association between sources and educational attainment. Additionally, multivariable logistic regression assessed the associations between sources and adverse outcomes (i.e., substance use, substance use disorders, and mental health) separately for each educational category.Results: College respondents were more likely to report "physician" and free from "friend/relative" and less likely to report "purchased" as sources. For most educational categories, "purchasing" prescription drugs was associated with adverse outcomes. Additionally, "theft/fake" prescription emerged as a source associated with adverse outcomes for college respondents, while "friend/relative" was associated with adverse outcomes for high school graduates that did not go on to college.Conclusions: This research has important clinical implications as it identified young adults with a college education as being less likely to obtain prescription drugs from sources known to be associated with adverse outcomes. It also highlighted how associations between sources and adverse outcomes vary based on educational attainment.
Assuntos
Analgésicos Opioides , Escolaridade , Uso Indevido de Medicamentos sob Prescrição , Evasão Escolar/estatística & dados numéricos , Transtornos Relacionados ao Uso de Substâncias , Tranquilizantes , Adolescente , Adulto , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/efeitos adversos , Feminino , Amigos , Inquéritos Epidemiológicos/estatística & dados numéricos , Humanos , Masculino , Médicos/estatística & dados numéricos , Uso Indevido de Medicamentos sob Prescrição/efeitos adversos , Uso Indevido de Medicamentos sob Prescrição/estatística & dados numéricos , Tranquilizantes/administração & dosagem , Tranquilizantes/efeitos adversos , Estados Unidos , Universidades , Adulto JovemRESUMO
Acute treatment of agitation in psychiatry is one of the urgent situations for which management recommendations are needed. Various existing international recommendations have been evaluated and adapted to our clinical practice and to the drugs available in Switzerland in order to propose a uniform management strategy in our hospital. This strategy includes a treatment choice algorithm with different options depending on the clinical situation and the possible route of administration. Dose recommendations for the oral and intramuscular routes, certain pharmacokinetic parameters, as well as risks of interactions and important warnings are also included in this clinical recommendation.
Le traitement aigu de l'agitation en psychiatrie fait partie des situations urgentes pour lesquelles des recommandations de prise en charge sont nécessaires. Diverses recommandations internationales existantes ont été évaluées et adaptées à notre pratique clinique ainsi qu'aux médicaments disponibles en Suisse afin de proposer une stratégie de prise en charge uniformisée au sein de notre hôpital. Cette stratégie inclut un algorithme de choix de traitement avec différentes options selon la situation clinique et la voie d'administration possible. Des recommandations de doses pour les voies orale et intramusculaire, certains paramètres pharmacocinétiques, ainsi que les risques d'interactions et des mises en garde importantes figurent également dans cette recommandation clinique.
Assuntos
Algoritmos , Tomada de Decisão Clínica , Psiquiatria/métodos , Tranquilizantes/administração & dosagem , Tranquilizantes/uso terapêutico , Teoria da Decisão , Vias de Administração de Medicamentos , Humanos , Suíça , Tranquilizantes/farmacocinéticaRESUMO
Violence and aggression are common problems encountered in prison, which frequently require clinical intervention. This increased prevalence is partially attributable to the high morbidity of psychiatric and personality disorders in prison inmates. As prisons are non-therapeutic environments, the provision of clinical care becomes more complex. This article examines the general principles of management of violence and aggression in prison settings, with a particular focus on the clinical and ethical considerations that guide pharmacological approaches. Use of psychotropic medication to address these problems is reserved for situations where there is (i) a diagnosable psychiatric disorder, or (ii) a significant risk of harm to an individual without urgent intervention. Initial focus should be on environmental and behavioural de-escalation strategies. Clear assessment for the presence of major mental illness is crucial, with appropriate pharmacological interventions being targeted and time-limited. Optimising management of any underlying psychiatric conditions is an important preventative measure. In the acute setting, rapid tranquilisation should be performed according to local guidelines with a focus on oral prior to parenteral administration. Clinicians must be mindful of capacity and consent issues amongst prisoners to protect patient rights and guide setting of care.
Assuntos
Agressão/efeitos dos fármacos , Transtornos Mentais/tratamento farmacológico , Prisões/ética , Tranquilizantes/administração & dosagem , Violência/prevenção & controle , Administração Oral , Agressão/psicologia , Direitos Humanos/ética , Humanos , Injeções , Transtornos Mentais/diagnóstico , Transtornos Mentais/psicologia , Prevalência , Prisioneiros/psicologia , Prisioneiros/estatística & dados numéricos , Prisões/estatística & dados numéricos , Resultado do Tratamento , Violência/psicologia , Violência/estatística & dados numéricosAssuntos
Clozapina/efeitos adversos , Edema/induzido quimicamente , Gabapentina/efeitos adversos , Transtornos Mentais/tratamento farmacológico , Doenças Orbitárias/induzido quimicamente , Tranquilizantes/efeitos adversos , Adulto , Clozapina/administração & dosagem , Gabapentina/administração & dosagem , Humanos , Masculino , Comportamento Autodestrutivo/tratamento farmacológico , Tranquilizantes/administração & dosagem , Adulto JovemRESUMO
PURPOSE: To investigate effect of metabolic syndrome on blood pressure during cataract surgery with topical anesthesia. DESIGN: A single-centered, retrospective case series. METHODS: Consecutive patients who were hospitalized and underwent phacoemulsification and insertion of intraocular lens with topical anesthesia in October 2016 were included. Perioperative blood pressure and pulse pressure were compared between patients with metabolic syndrome (metabolic group) and sex- and age-matched patients without metabolic syndrome (nonmetabolic group) at six time points: on admission, in the morning of the operation, 2âhours before the operation, at the point of entering the operation room, during the operation, and after the operation. Perioperative use of etizolam and nicardipine was compared between the two groups. RESULTS: Thirty patients in the metabolic group and 30 in the nonmetabolic group were included. There was no difference in changes compared with the values on admission in systolic pressure and pulse pressure at any examination point between the two groups. There was no difference in changes in diastolic pressure between the two groups, except for at 2âhours before the operation (1.4â±â9.6âmm Hg in the metabolic group vs -6.2â±â8.5âmm Hg in the nonmetabolic group; Pâ=â0.044). The number of patients who were administered etizolam was 5/30 (16.7%) in the metabolic group and 2/30 (6.7%) in the nonmetabolic group, showing no significant difference. No patients were administered intravenous nicardipine in either group. CONCLUSIONS: Well-controlled metabolic syndrome did not affect the changes in perioperative blood pressure during cataract surgery with topical anesthesia.
Assuntos
Pressão Sanguínea/fisiologia , Implante de Lente Intraocular , Síndrome Metabólica/fisiopatologia , Facoemulsificação , Idoso , Idoso de 80 Anos ou mais , Diazepam/administração & dosagem , Diazepam/análogos & derivados , Feminino , Humanos , Pressão Intraocular/fisiologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Tranquilizantes/administração & dosagemRESUMO
AIMS AND OBJECTIVES: To identify key determinants, which lead to the decision to apply physical or chemical restraint on the critical care unit. BACKGROUND: Psychomotor agitation and hyperactive delirium are frequently cited as clinical rationale for initiating chemical and physical restraint in critical care. Current restraint guidance is over a decade old, and wide variations in nursing and prescribing practice are evident. It is unclear whether restraint use is grounded in evidence-based practice or custom and culture. STUDY DESIGN: Integrative review. METHOD: Seven health sciences databases were searched to identify published and grey literature (1995-2019), with additional hand-searching. The systematic deselection process followed PRISMA guidance. Studies were included if they identified physical or chemical restraint as a method of agitation management in adult critical care units. Quality appraisal was undertaken using Mixed Methods Appraisal Tool. Data were extracted, and thematic analysis undertaken. RESULTS: A total of 23 studies were included. Four main themes were identified: the lack of standardised practice, patient characteristics associated with restraint use, the struggle in practice and the decision to apply restraint. CONCLUSIONS: There are wide variations in restraint use despite the presence of international guidance. Nurses are the primary decision-makers in applying restraint and report that caring for delirious patients is physically and psychologically challenging. The decision to restrain can be influenced by the working environment, patient behaviours and clinical acuity. Enhanced clinical support and guidance for nurses caring for delirious patients is indicated. RELEVANCE TO CLINICAL PRACTICE: Delirium and agitation pose a potential threat to patient safety and the maintenance of life-preserving therapies. Restraint is viewed as one method of preserving patient safety. However, use appears to be influenced by previous adverse experiences and subjective patient descriptors, rather than robust evidence-based knowledge. The need for a precise language to describe restraint and quantify when it becomes necessary is indicated.
Assuntos
Enfermagem de Cuidados Críticos/métodos , Tomada de Decisões , Agitação Psicomotora/enfermagem , Restrição Física/normas , Adulto , Delírio/enfermagem , Humanos , Unidades de Terapia Intensiva , Pessoa de Meia-Idade , Relações Médico-Enfermeiro , Restrição Física/efeitos adversos , Tranquilizantes/administração & dosagemRESUMO
BACKGROUND: The nonmedical use of prescribed medicines among adolescents has increased significantly in recent years. Our study was designed to describe the prevalence of the nonmedical use of tranquilizers, sedatives, and sleeping pills (TSSp) among the school-age population residing in Spain from a gender perspective, and to identify factors associated with such use. METHODS: Nationwide, epidemiological, cross-sectional study on the nonmedical use during the previous 30 days, of TSSp by the Spanish school population. We used individualized secondary data retrieved from the 2004, 2006, 2008, 2010, 2012 and 2014 Spanish state survey on Drug Use in Secondary Education and a total of 179,114 surveys from respondents aged 14 to 18 years. Using logistic multivariate regression models, we estimated the independent effect of each of these variables on the nonmedical use of medicines. Two models were generated- one for females and one for males. RESULTS: 2.86% (5116) of the Spanish school population of both sexes made nonmedical use of TSSp. Prevalence was greater among girls than among boys for all the study years. Patterns of nonmedical use among female adolescents were related to alcohol, tobacco and marijuana use. Consumption of illegal psychoactive substances, other than marijuana, was the variable showing the greatest value among male teenagers (aOR 6.21 (95% CI 4.97-7.77). CONCLUSIONS: The prevalence of the nonmedical use of TSSp is higher in girls than in boys. The influence of legal and illegal psychoactive substances leads to a higher likelihood of nonmedical use of TSSp in high-school students in Spain.
Assuntos
Hipnóticos e Sedativos/administração & dosagem , Uso Indevido de Medicamentos sob Prescrição/estatística & dados numéricos , Tranquilizantes/administração & dosagem , Adolescente , Estudos Transversais , Estudos Epidemiológicos , Feminino , Humanos , Masculino , Fatores Sexuais , Medicamentos Indutores do Sono/administração & dosagem , EspanhaRESUMO
The aims of this study were: (a) to estimate time trends in the prevalence of the co-use of cannabis and other cannabis-based products (CBP) with the misuse of tranquilizers, sedatives, and sleeping pills (TSSp) between 2009 and 2015; and (b) to identify the factors associated with the probability of the co-use of CBP with TSSp misuse during this period among Spanish younger adults (15-34 years old). We analyzed data collected from the Spanish National Surveys on Alcohol and Other Drugs (EDADES) in 2009, 2011, 2013, and 2015. CBP co-use with TSSp misuse were the dependent variables. We also analyzed sociodemographic features, self-perceived health status, lifestyle habits, perceived health risk of consumption, and perceived availability of substance using logistic regression models. The prevalence of CBP co-use with TSSp misuse has decreased in Spain. The factors associated with co-use were a lack of education (OR 2.34), alcohol (OR 7.2), tobacco (OR 6.3) and other illicit psychoactive drug (OR 6.5) consumption, perceived non-health risk for the consumption of CBP and TSSp (OR 3.27), and perceived availability of CBP (OR 2.96). Our study identified several factors that appear to affect CBP and TSSp co-use in younger adults, with potential implications for healthcare providers.
Assuntos
Fumar Maconha/epidemiologia , Medicamentos Indutores do Sono/administração & dosagem , Tranquilizantes/administração & dosagem , Adolescente , Adulto , Feminino , História do Século XXI , Humanos , Masculino , Prevalência , Autoimagem , Espanha/epidemiologia , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Adulto JovemRESUMO
Etizolam is a drug from the thienotriazoldiazepine class, widely prescribed as anxiolytic due to its apparently secure toxicological profile. Nevertheless, some recent cases of etizolam dependence, intoxications and fatalities associated to its abuse have been reported in the international literature. For this reason, the drug listed as new psychoactive substance (NPS) by the World Health Organization (WHO) since 2015. Euphoric effect at high dosage is the first cause of its recreational use that has determined a wider distribution in the illicit market. An experimental study was performed to obtain evidence that etizolam at low therapeutic dosages is a drug with negligible influence on the psychomotor performances involved in driving. The psychomotor performance was assessed by performing different tests, such as critical tracking task (CTT), critical flicker fusion (CFF), choice reaction time (CRT), visual vigilance task (VVT), response competition test (RCT) in a group of 16 healthy volunteers after a single administration of etizolam at two different dosages (0.25 mg or 1.00 mg) in comparison to placebo. The test results showed that etizolam at 0.25 mg and 1.00 mg had no significant effect on vigilance, short term memory, psychomotor coordination or speed in decision making. Differently, abuse of etizolam to obtain the euphoric effects at presumably high dosages or in combination with other psychoactive substances could be fatal. The negligible side effects on mental and behavioral function demonstrated by this study, could represent an incitement to abuse, which can be strongly discouraged with correct information on differences between its correct use and its misuse.
Assuntos
Diazepam/análogos & derivados , Desempenho Psicomotor/efeitos dos fármacos , Tranquilizantes/administração & dosagem , Adulto , Estudos Cross-Over , Tomada de Decisões/efeitos dos fármacos , Diazepam/administração & dosagem , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Voluntários Saudáveis , Humanos , Masculino , Memória de Curto Prazo/efeitos dos fármacos , Testes Neuropsicológicos , Tempo de Reação/efeitos dos fármacos , Adulto JovemRESUMO
In psychiatry, agitated / aggressive patients are often treated with de-escalation techniques. If this does not work, physical or chemical restrains are required; but in the event of resistance, seclusion is applied. We report the findings of baseline study of experiences of physical and chemical restraints in a tertiary care hospital in Karachi, where 104 files were evaluated retrospectively. The mean age of patients was 32.5 ±14.3 years with 54.8% men, while the average length of stay was 11.5 ±9.3 days. Agitation, violent behaviour, and aggression were the most common indications for restraints. In total, 94.5% of patients had both physical and chemical restraints with the latter being used as the first choice in 70 patients; whereas, 67.1% of patients' families were not informed before application of restraints. The seclusion need assessment was conducted in 4.1% of patients.
Assuntos
Agressão/psicologia , Isolamento de Pacientes , Agitação Psicomotora/psicologia , Restrição Física/métodos , Tranquilizantes/administração & dosagem , Violência/prevenção & controle , Adulto , Feminino , Humanos , Tempo de Internação , Masculino , Transtornos Mentais/terapia , Pessoa de Meia-Idade , Restrição Física/estatística & dados numéricos , Violência/psicologiaAssuntos
Erupções Acneiformes/induzido quimicamente , Transtorno Bipolar/tratamento farmacológico , Lamotrigina/efeitos adversos , Compostos de Lítio/efeitos adversos , Tranquilizantes/efeitos adversos , Idoso , Quimioterapia Combinada , Feminino , Humanos , Lamotrigina/administração & dosagem , Compostos de Lítio/administração & dosagem , Tranquilizantes/administração & dosagemRESUMO
BACKGROUND: Bipolar and other psychiatric disorders are associated with considerably increased risk of suicidal behaviour, which may include self-poisoning with medication used to treat the disorder. Therefore, choice of medication for treatment should include consideration of toxicity, especially for patients at risk. The aim of this study was to estimate the relative toxicity of specific drugs within two drug categories, antipsychotics and mood stabilizers, using large-scale databases to provide evidence that could assist clinicians in making decisions about prescribing, especially for patients at risk of suicidal behaviour. METHOD: Two indices were used to assess relative toxicity of mood stabilisers and antipsychotics: case fatality (the ratio between rates of fatal and non-fatal self-poisoning) and fatal toxicity (the ratio between rates of fatal self-poisoning and prescription). Mood stabilisers assessed included lithium [reference], sodium valproate, carbamazepine, and lamotrigine, while antipsychotics included chlorpromazine [reference], clozapine, olanzapine, quetiapine and risperidone. Fatal self-poisoning (suicide) data were provided by the Office for National Statistics (ONS), non-fatal self-poisoning data by the Multicentre Study of Self-harm in England, and information on prescriptions by the Clinical Practice Research Datalink. The primary analysis focussed on deaths due to a single drug. Cases where the drug of interest was listed as the likely primary toxic agent in multiple drug overdoses were also analysed. The study period was 2005-2012. RESULTS: There appeared to be little difference in toxicity between the mood stabilisers, except that based on case fatality where multiple drug poisonings were considered, carbamazepine was over twice as likely to result in death relative to lithium (OR 2.37 95% CI 1.16-4.85). Of the antipsychotics, clozapine was approximately18 times more likely to result in death when taken in overdose than chlorpromazine (single drug case fatality: OR 18.53 95% CI 8.69-39.52). Otherwise, only risperidone differed from chlorpromazine, being less toxic (OR 0.06 95% CI 0.01-0.47). CONCLUSIONS: There was little difference in toxicity of the individual mood stabilisers. Clozapine was far more toxic than the other antipsychotics. The findings are relevant to prescribing policy, especially for patients at particular risk of suicidal behaviour.
Assuntos
Antipsicóticos , Overdose de Drogas , Conduta do Tratamento Medicamentoso , Transtornos Mentais , Risco Ajustado/métodos , Comportamento Autodestrutivo , Prevenção do Suicídio , Suicídio , Tranquilizantes , Adulto , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Antipsicóticos/classificação , Overdose de Drogas/etiologia , Overdose de Drogas/prevenção & controle , Overdose de Drogas/psicologia , Inglaterra , Feminino , Humanos , Transtornos Mentais/complicações , Transtornos Mentais/tratamento farmacológico , Transtornos Mentais/psicologia , Padrões de Prática Médica , Comportamento Autodestrutivo/prevenção & controle , Comportamento Autodestrutivo/psicologia , Suicídio/psicologia , Suicídio/estatística & dados numéricos , Tranquilizantes/administração & dosagem , Tranquilizantes/efeitos adversos , Tranquilizantes/classificaçãoAssuntos
Catatonia/tratamento farmacológico , Síndrome Maligna Neuroléptica/diagnóstico , Abscesso do Psoas/diagnóstico , Transtornos Psicóticos/tratamento farmacológico , Tranquilizantes/efeitos adversos , Adulto , Catatonia/etiologia , Diagnóstico Diferencial , Feminino , Humanos , Síndrome Maligna Neuroléptica/etiologia , Abscesso do Psoas/complicações , Tranquilizantes/administração & dosagemRESUMO
Cyclical menstrual psychosis is an uncommon, generally a self-limiting mental illness that occurs only in females. It is associated with other menstruation-related disorders and stressful psychogenic factors. Nonetheless, many cases remain unrecognized due to poor awareness of its presence. A young female who presented with psychotic and mood symptoms during each cycle of menstruation was admitted to the psychiatric inpatient unit. There was severe disruption in her activities of daily living and socio-occupational functioning. Treatment involved bio-psycho-social approach in collaboration with Ob-Gyn team with symptoms responding well to a combination of valproic acid and risperidone. Severe affective instability with evident psychosis during menstrual cycle should be evaluated for cyclical menstrual psychosis.
Assuntos
Distúrbios Menstruais/fisiopatologia , Transtornos Psicóticos/fisiopatologia , Adulto , Feminino , Humanos , Distúrbios Menstruais/tratamento farmacológico , Transtornos Psicóticos/tratamento farmacológico , Risperidona/administração & dosagem , Tranquilizantes/administração & dosagem , Ácido Valproico/administração & dosagem , Adulto JovemRESUMO
OBJECTIVE: This multicenter, multinational, cross-sectional study aimed to investigate clinical characteristics and treatment outcomes associated with augmentation/combination treatment strategies in major depressive disorder (MDD). METHOD: Sociodemographic, clinical, and treatment features of 1410 adult MDD patients were compared between MDD patients treated with monotherapy and augmentation/combination medication using descriptive statistics, analyses of covariance (ancova), and Spearman's correlation analyses. RESULTS: 60.64% of all participants received augmentation and/or combination strategies with a mean number of 2.18 ± 1.22 simultaneously prescribed psychiatric drugs. We found male gender, older age, Caucasian descent, higher weight, low educational status, absence of occupation, psychotic symptoms, melancholic and atypical features, suicide risk, in-patient treatment, longer duration of hospitalization, some psychiatric comorbidities (panic disorder, agoraphobia, obsessive-compulsive disorder, and bulimia nervosa), comorbid somatic comorbidity in general and concurrent hypertension, thyroid dysfunction, diabetes, and heart disease in particular, higher current and retrospective Montgomery and Åsberg Depression Rating Scale total scores, treatment resistance, and higher antidepressant dosing to be significantly associated with augmentation/combination treatment. These findings were corroborated when examining the number of concurrently administered psychiatric drugs in the statistical analyses. CONCLUSION: Our findings suggest a clear association between augmentation/combination strategies and treatment-resistant/difficult-to-treat MDD conditions characterized by severe symptomatology and high amount of psychiatric and somatic comorbidities.
Assuntos
Antidepressivos/administração & dosagem , Antipsicóticos/administração & dosagem , Benzodiazepinas/administração & dosagem , Comorbidade , Transtorno Depressivo Maior/tratamento farmacológico , Transtorno Depressivo Resistente a Tratamento/tratamento farmacológico , Tranquilizantes/administração & dosagem , Adulto , Estudos Transversais , Transtorno Depressivo Maior/epidemiologia , Transtorno Depressivo Maior/fisiopatologia , Transtorno Depressivo Resistente a Tratamento/epidemiologia , Transtorno Depressivo Resistente a Tratamento/fisiopatologia , Sinergismo Farmacológico , Quimioterapia Combinada , Europa (Continente)/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
BACKGROUND: People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be used in such situations. OBJECTIVES: To evaluate the effects of intramuscular aripiprazole in the treatment of psychosis-induced aggression or agitation (rapid tranquillisation). SEARCH METHODS: On 11 December 2014 and 11 April 2017, we searched the Cochrane Schizophrenia Group's Study-based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. SELECTION CRITERIA: All randomised controlled trials (RCTs) that randomised people with psychosis-induced aggression or agitation to receive either intramuscular aripiprazole or another intramuscular intervention. DATA COLLECTION AND ANALYSIS: We independently inspected citations and, where possible, abstracts, ordered papers and re-inspected and quality assessed these. We included studies that met our selection criteria. At least two review authors independently extracted data from the included studies. We chose a fixed-effect model. We analysed dichotomous data using risk ratio (RR) and the 95% confidence intervals (CI). We analysed continuous data using mean differences (MD) and their CIs. We assessed risk of bias for included studies and used GRADE to create 'Summary of findings' tables. MAIN RESULTS: Searching found 63 records referring to 21 possible trials. We could only include three studies, all completed over the last decade, with 885 participants, of which 707 were included for quantitative analyses in this systematic review. Due to limited comparisons, small size of trials and a paucity of investigated and reported 'pragmatic' outcomes, evidence was mostly graded as low or very low quality. No trials reported useful data for one of our primary outcomes of tranquil or asleep by 30 minutes. Economic outcomes were also not reported in the trials.When compared with placebo, fewer people in the aripiprazole group needed additional injections compared to the placebo group (2 RCTs, n = 382, RR 0.69, 95% CI 0.56 to 0.85, very low-quality evidence). Clinically important improvement in agitation at two hours favoured the aripiprazole group (2 RCTs, n = 382, RR 1.50, 95% CI 1.17 to 1.92, very low-quality evidence). The numbers of non-responders after the first injection also favoured aripiprazole (1 RCT, n = 263, RR 0.49, 95% CI 0.34 to 0.71, low-quality evidence). Although no effect was found, more people in the aripiprazole compared to the placebo group experienced adverse effects (1 RCT, n = 117, RR 1.51, 95% CI 0.93 to 2.46, very low-quality evidence).Aripiprazole required more injections compared to haloperidol (2 RCTs, n = 477, RR 1.28, 95% CI 1.00 to 1.63, very low-quality evidence), with no significant difference in agitation (2 RCTs, n = 477, RR 0.94, 95% CI 0.80 to 1.11, very low-quality evidence), and similar non-responders after first injection (1 RCT, n = 360, RR 1.18, 95% CI 0.78 to 1.79, low-quality evidence). Aripiprazole and haloperidol did not differ when taking into account the overall number of people that experienced at least one adverse effect (1 RCT, n = 113, RR 0.91, 95% CI 0.61 to 1.35, very low-quality evidence).Compared to aripiprazole, olanzapine was better at reducing agitation (1 RCT, n = 80, RR 0.77, 95% CI 0.60 to 0.99, low-quality evidence) and had a more favourable effect on global state change scores (1 RCT, n = 80, MD 0.58, 95% CI 0.01 to 1.15, low-quality evidence), both at two hours. No differences were found in terms of experiencing at least one adverse effect during the 24 hours after treatment (1 RCT, n = 80, RR 0.75, 95% CI 0.45 to 1.24, very low-quality evidence). However, participants allocated to aripiprazole experienced less somnolence (1 RCT, n = 80, RR 0.25, 95% CI 0.08 to 0.82, low-quality evidence). AUTHORS' CONCLUSIONS: The available evidence is of poor quality but there is some evidence aripiprazole is effective compared to placebo and haloperidol, but not when compared to olanzapine. However, considering that evidence comes from only three studies, caution is required in generalising these results to real-world practice. This review firmly highlights the need for more high-quality trials on intramuscular aripiprazole in the management of people with acute aggression or agitation.
Assuntos
Agressão/efeitos dos fármacos , Antipsicóticos/administração & dosagem , Aripiprazol/administração & dosagem , Agitação Psicomotora/tratamento farmacológico , Agressão/psicologia , Antipsicóticos/efeitos adversos , Aripiprazol/efeitos adversos , Benzodiazepinas/administração & dosagem , Haloperidol/administração & dosagem , Humanos , Injeções Intramusculares , Olanzapina , Agitação Psicomotora/psicologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Tranquilizantes/administração & dosagemRESUMO
BACKGROUND: When administering psychotropic drugs during pregnancy not only the potential teratogenic effects on the child must be addressed but also the fetotoxic implications for pregnancy and/or the peripartum phase as well as possible neurocognitive developmental disorders must be considered. OBJECTIVE: Evaluation of the risks and benefits of administering psychotropic drugs during pregnancy or for women who wish to become pregnant. METHODS: The literature has been reviewed with the purpose of providing information on psychotropic drugs which can safely be administered during pregnancy. The review considers antipsychotics as well as tranquilizers and hypnotics. RESULTS: Data are available for a multitude of psychotropic drugs that allow a safe estimation on their suitability for use during pregnancy. CONCLUSION: When treating mental illnesses during pregnancy the option of administering drugs must not principally be ruled out. What is required is an individual assessment of benefits and risks. The risk of an untreated mental illness versus the benefit of a suitable treatment, which may include the use of medication and the potential harm to the infant must be evaluated. If certain rules are observed and a suitable drug is selected the risk to the newborn child and/or mother during pregnancy can be minimized. During pregnancy, therapeutic drug monitoring is indicated and increases the safety for use of drugs and preventing harm to both mother and infant.
Assuntos
Anormalidades Induzidas por Medicamentos/prevenção & controle , Antipsicóticos/administração & dosagem , Hipnóticos e Sedativos/administração & dosagem , Transtornos Mentais/tratamento farmacológico , Complicações na Gravidez/tratamento farmacológico , Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente , Tranquilizantes/administração & dosagem , Anormalidades Induzidas por Medicamentos/etiologia , Esquema de Medicação , Monitoramento de Medicamentos/métodos , Quimioterapia Combinada/métodos , Medicina Baseada em Evidências , Feminino , Humanos , Troca Materno-Fetal/efeitos dos fármacos , Gravidez , Efeitos Tardios da Exposição Pré-Natal/prevenção & controle , Psicofarmacologia , Resultado do TratamentoRESUMO
Capture and translocation are important tools for managing and studying large ungulates. Although widely used, many established field practices cause fear and stress in subject animals that can hamper overall effectiveness and safety. Over the last 10 years we have been exploring uses of tranquilizer combinations as adjuncts to wild ungulate capture and translocation work in Colorado, USA. Our approaches have been tailored to various field applications to reduce fear and stress, facilitate handling, and improve the overall success of capture and translocation for research or management purposes. For physical capture (drop net or helicopter-net gunning) with local release, combinations of midazolam and azaperone administered immediately upon capture provide transient tranquilization and muscle relaxation during manual restraint and handling to prevent hyperthermia and capture myopathy. For extended tranquilization (during transport and overnight holding), adding a sustained-release haloperidol formulation provides calming effects for at least 24-48 h. In our assessment, appropriate and adaptive use of these tranquilizer combinations benefits captured animals without impeding management or research goals.